Dysregulation of miRNA expression in patients with chronic myelogenous leukemia at diagnosis: a systematic review-Reference-Cited by-同舟云学术

Dysregulation of miRNA expression in patients with chronic myelogenous leukemia at diagnosis: a systematic review

Published:2023-12 Issue:24 Volume:17 Page:1021-1029
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Parsa-kondelaji Mohammad¹,Musavi Maryam²,Barzegar Faezeh¹,Abbasian Neda³,Rostami Mehrdad¹,R Seyedtaghia Mohammad⁴,S Hashemi Seyyed⁴,Modi Mahdiyeh²⁵,Nikfar Banafsheh⁶,A Momtazi-Borojeni Amir²⁵^ORCID

Affiliation:

1. Department of Hematology & Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2. Healthy Ageing Research Centre, Neyshabur University of Medical Sciences, Neyshabur, Iran

3. Hematology & Blood Banking Center, Emam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

4. Department of Medical Genetics & Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5. Department of Medical Biotechnology, Faculty of Medicine, Neyshabur University of Medical Sciences, Neyshabur, Iran

6. Pars Advanced and Minimally Invasive Medical Manners Research Center, Pars Hospital, Iran University of Medical Sciences, Tehran, Iran

Abstract

Aim: The present systematic review aimed to explore miRNAs as a potential biomarker for early diagnosis of chronic myeloid leukemia (CML). Materials & methods: A systematic search was conducted in three electronic databases, including Web of Science, Scopus and PubMed, to obtain relevant articles investigating the alteration of miRNA expression in patients with CML. Results: The authors found miRNAs whose expression changes are effective in the induction of CML disease. Among them, miR-21 and miR-155 were identified as the most common miRNAs with increased expression and miR-150 and miR-146 as the most common miRNAs with decreased expression. Conclusion: miRNAs can be used as an indicator for the early detection and treatment of CML phase.

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2023-0575

Reference73 articles.

1. MicroRNA-370-3p inhibits cell proliferation and induces chronic myelogenous leukaemia cell apoptosis by suppressing PDLIM1/Wnt/β-catenin signalling

2. Molecular biology of bcr-abl1–positive chronic myeloid leukemia

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances